ResMed quarterly update to test full-year guidance
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
ResMed (ASX:RMD) reports quarterly results this week, giving the market its first look at performance against full-year guidance. Analysts will focus on gross margin trends, the Astral ventilator sales suspension, software divestment progress, and how new weight-loss medicines affect sleep apnoea demand. Capital management and pipeline updates are also in view.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.